J&J-Bayer Blood Thinner May Enter $1 Billion Market

A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rivals failed in reducing deaths following a heart attack promises to give the companies entry to a $1 billion-plus market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.